NCT02914652View on ClinicalTrials.gov

The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

October 15, 2016

Primary Completion Date

July 1, 2017

Study Completion Date

January 1, 2018

Conditions
Ventricular Septal Defect
Interventions
DRUG

Salbutamol

Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.

DRUG

Norflouran (Placebo Evohaler(R) )

Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.

Trial Locations (1)

8000

Dept. of Cardiothoracic and Vascular Surgery, Aarhus

All Listed Sponsors
lead

University of Aarhus

OTHER

NCT02914652 - The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects. | Biotech Hunter | Biotech Hunter